On the use of positron counting for radio-Assay in nuclear pharmaceutical production

Current techniques for the measurement of radioactivity at various points during PET radiopharmaceutical production and R&D are based on the detection of the annihilation gamma rays from the radionuclide in the labelled compound. The detection systems to measure these gamma rays are usually variations of NaI or CsF scintillation based systems requiring costly and heavy lead shielding to reduce background noise. These detectors inherently suffer from low detection efficiency, high background noise and very poor linearity. They are also unable to provide any reasonably useful position information. A novel positron counting technique is proposed for the radioactivity assay during radiopharmaceutical manufacturing that overcomes these limitations. Detection of positrons instead of gammas offers an unprecedented level of position resolution of the radiation source (down to sub-mm) thanks to the nature of the positron interaction with matter. Counting capability instead of charge integration in the detector brings the sensitivity down to the statistical limits at the same time as offering very high dynamic range and linearity from zero to any arbitrarily high activity. This paper reports on a quantitative comparison between conventional detector systems and the proposed positron counting detector. - Highlights: • A novel positron counting technique is proposed for the radioactivity assay during radiopharmaceutical manufacturing. • Traditional detection methods of measuring the annihilation gamma emission of the positrons suffer from many drawbacks. • Advantages of direct positron detection: linearity, sensitivity, dynamic range, precise position information of activity. • A multi-purpose compact (150x60x20 mm) detector of positrons was developed to suit needs of radio labs.